Vicapsys Life Sciences, Inc.
VICP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.8M
Close$
$-0.02
103.9% downside
Current Fair Value
103.9% downsideOvervalued by 103.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $17.80 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.02 |
| Beta | -4.13 |
| Outstanding Shares | 35,371,299 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -28.2 |
|---|---|
| PEG | 66.57 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
July 20, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Vicapsys Life Sciences, Inc.
2 employees
CEO: Federico Pier
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, spe...